Related Experiment Video
Updated: Aug 20, 2026

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human
Birgit Morgenstern1, Martin Michaelis, Patrick C Baer
1Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Str. 40, 60596 Frankfurt, Germany.
Abstract:
Initial in vitro investigations demonstrated type I interferons (IFNs: IFN-alpha, IFN-beta) to inhibit replication of SARS coronavirus (SARS-CoV), but found the nucleoside analogue ribavirin ineffective in Vero cells. In this report, ribavirin was shown to inhibit SARS-CoV replication in five different cell types of animal or human origin at therapeutically achievable concentrations. Since clinical anti-SARS-CoV activity of type I interferons or ribavirin is limited, we investigated the combination of IFN-beta and ribavirin. Determination of the virus yield indicated highly synergistic anti-SARS-CoV action of the combination suggesting the consideration of ribavirin plus IFN-beta for the treatment of SARS.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Coronavirus
Viral Recombination
Respiratory Syncytial Virus Disease
Antiviral Nucleoside Inhibitors

